Aqueous ophthalmic solutions of phentolamine and medical uses thereof
The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
1. An aqueous ophthalmic solution consisting of:
a. 0.1% (w/v) to 4% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof;
b. 1% (w/v) to 6% (w/v) of at least one polyol compound having a molecular weight less than 250 g/mol;
c. 0.1 mM to 10 mM of at least one buffer; and
d. water;
wherein the solution has a pH in the range of 4.0 to 7.5.
2. The solution of claim 1 , wherein:
(a) the at least one polyol compound is mannitol, glycerol, propylene glycol, ethylene glycol, sorbitol, or xylitol;
(b) the at least one polyol compound is mannitol;
(c) the at least one polyol compound is glycerol;
(d) the at least one polyol compound is propylene glycol;
(e) the at least one polyol compound is mannitol and glycerol;
(f) the at least one polyol compound is mannitol and propylene glycol;
(g) the at least one polyol compound is glycerol and propylene glycol;
(h) from 2% (w/v) to 5% (w/v) of the at least one polyol compound is present in the solution;
(i) from 3.5% (w/v) to 4.5% (w/v) of the at least one polyol compound is present in the solution; or
(j) 4% (w/v) of the at least one polyol compound is present in the solution.
3. The solution of claim 1 , wherein:
(a) the buffer is present at a concentration in the range of 2 mM to 4 mM;
(b) the buffer is present at a concentration of 3 mM;
(c) the buffer comprises an alkali metal alkylcarboxylate;
(d) the buffer comprises an alkali metal acetate; or
(e) the buffer comprises sodium acetate.
4. The solution of claim 1 , wherein the solution has a pH in the range of 4.5 to 6.0, or the solution has a pH in the range of 4.7 to 5.1.
5. The solution of claim 1 , wherein:
(a) from 0.5% (w/v) to 2% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof is present in the solution;
(b) 1% (w/v) of phentolamine or a pharmaceutically acceptable salt thereof is present in the solution;
(c) from 0.1% (w/v) to 4% (w/v) of phentolamine mesylate is present in the solution;
(d) from 0.25% (w/v) to 2% (w/v) of phentolamine mesylate is present in the solution;
(e) from 0.25% (w/v) to 1% (w/v) of phentolamine mesylate is present in the solution; or
(f) 1% (w/v) of phentolamine mesylate is present in the solution.
6. The solution of claim 1 , wherein the solution consists of:
a. 0.25% (w/v) to 2% (w/v) of phentolamine mesylate;
b. 1% (w/v) to 6% (w/v) of at least one polyol compound selected from the group consisting of mannitol, glycerol, and propylene glycol;
c. 1 mM to 6 mM of an alkali metal acetate buffer; and
d. water;
wherein the solution has a pH in the range of 4.5 to 5.5.
7. The solution of claim 6 , wherein from 0.25% (w/v) to 1% (w/v) of phentolamine mesylate is present in the solution.
8. The solution of claim 7 , wherein from 1% (w/v) to 4% (w/v) mannitol is present in the solution.
9. The solution of claim 8 , wherein 4% (w/v) mannitol is present in the solution.
10. The solution of claim 7 , wherein the alkali metal acetate is sodium acetate.
11. The solution of claim 8 , wherein the alkali metal acetate is sodium acetate.
12. The solution of claim 9 , wherein 3 mM sodium acetate is present in the solution.
13. The solution of claim 1 , wherein the solution consists of:
a. 0.25% (w/v) to 2% (w/v) of phentolamine mesylate;
b. 3% (w/v) to 5% (w/v) of mannitol;
c. 2 mM to 4 mM of sodium acetate buffer; and
d. water;
wherein the solution has a pH in the range of 4.5 to 5.2.
14. The solution of claim 1 , wherein the solution consists of:
a. 0.5% (w/v) to 1% (w/v) of phentolamine mesylate;
b. 4% mannitol;
c. 3 mM sodium acetate buffer; and
d. water;
wherein the solution has a pH in the range of 4.6 to 5.2.
15. The solution of claim 6 , wherein:
(a) less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 12 weeks;
(b) less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 24 weeks; or
(c) less than 7% of the phentolamine mesylate degrades upon storage at 40° C. for 12 weeks.
16. The solution of claim 11 , wherein:
(a) less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 12 weeks;
(b) less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 24 weeks; or
(c) less than 7% of the phentolamine mesylate degrades upon storage at 40° C. for 12 weeks.
17. The solution of claim 14 , wherein:
(a) less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 12 weeks;
(b) less than 2% of the phentolamine mesylate degrades upon storage at 25° C. for 24 weeks; or
(c) less than 7% of the phentolamine mesylate degrades upon storage at 40° C. for 12 weeks.
18. The solution of claim 1 , wherein the at least one polyol compound is mannitol; the buffer is present at a concentration in the range of 2 mM to 4 mM; and the solution has a pH in the range of 4.7 to 5.1.